Skip to main content

Table 2 Country-specific proportions of physicians who regularly tested for biomarkers in NMIBC patients

From: Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

Biomarker FR (n = 39) DE (n = 39) IT (n = 39) ES (n = 49) UK (n = 36) US (n = 180) JP (n = 91) CN (n = 35)
PD-1/PD-L1 41% 56% 38% 18% 39% 27% 7% 54%
CEA 18% 21% 51% 12% 4% 14% 3% 83%
NMP22 5% 13% 3% 4% 3% 24% 21% 20%
Inflammatory markers† 5% 13% 21% 4% 2% 13% 1% 51%
Tp53 10% 13% 15% 4% 1% 18% 2% 31%
FGFR3 13% 15% 5% 6% 5% 1% 2% 9%
BLCA-4 8% 5% 5% 6% 19% 1% 1% 20%
BLCA-1 10% 8% 5% 4% 5% 12% 3% 23%
Chromosome aneuploidy‡ 3% 3% 3% 0% 1% 16% 1% 20%
HRAS 0% 5% 5% 4% 1% 9% 3% 11%
Loss of 9p21 locus 3% 8% 3% 2% 3% 8% 8% 0%
TERT promoter 0% 5% 5% 0% 3% 6% 2% 6%
Mucins (LDQ10/M344) 0% 3% 0% 2% 1% 5% 1% 9%
cFH 3% 3% 0% 0% 3% 3% 3% 3%
Other 3% 0% 3% 2% 3% 1% 0% 0%
None 49% 38% 31% 67% 33% 51% 70% 11%
  1. CEA: carcinoembryonic antigen; †Inflammatory markers (cytokines); ‡Chromosome 3, 7, 17 aneuploidy
  2. CN: China; DE: Germany; ES: Spain; FR: France; IT: Italy; JP: Japan; UK: United Kingdom; US: United States